Relay Therapeutics, Inc. research snapshot
RLAY AI stock analysis reads Relay Therapeutics as a high-risk, high-reward clinical-stage precision medicine company that has delivered impressive early-stage data for its lead asset zovegalisib (RLY-2608) in PIK3CA-mutant breast cancer. At the July 12, 2026 data cutoff, RLAY traded near $20.01 with a verified market capitalization near $4.36 billion, holding approximately $642 million in cash with minimal debt. The stock has rallied over 436% in the past year on positive clinical data but remains pre-revenue and pre-profits with quarterly net losses around $73 million. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$20.01
Market cap
$4.36 billion
AI score
62 / 100
Rating
High-risk biotech with promising PI3Ka data, watch Phase 3 readout
Trend status
Strong uptrend above all key moving averages after 436% yearly gain
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Relay Therapeutics combines computational (Dynamo platform) and experimental drug discovery to target previously undruggable proteins, with lead asset zovegalisib showing best-in-class potential in PI3Ka-mutant breast cancer and vascular anomalies. | Medium |
| Moat | The Dynamo platform and mutant-selective PI3Ka approach create technical differentiation, but durability depends on clinical execution, patent protection, and whether competitors can develop similar selective inhibitors. | Low-medium |
| Management | Management has advanced zovegalisib from discovery to Phase 3, outlicensed RLY-4008 to Elevar for non-dilutive capital, and secured a $642M cash position, but historical share dilution through follow-on offerings is a concern. | Medium |
| Financial trend | Pre-revenue biotech with TTM collaboration revenue of $10.7M, TTM net loss of $272.7M, and $642M cash providing approximately 2 years of runway at current burn rate. | High |
| Valuation | At $20.01, RLAY trades at 6.8x book value and enterprise value of approximately $3.75 billion. Valuation is based on pipeline probability-adjusted NPV rather than earnings, with analyst targets ranging from $18 to $28. | Low-medium |
| Technical trend | Strong uptrend with price above all key moving averages (8-day SMA $19.27, 20-day SMA $17.68, 50-day SMA $15.11, 200-day SMA $10.33). RSI at 66.3 approaching overbought. | Medium |
| Risk level | Very high. Binary Phase 3 readout risk, pre-revenue profile, equity dilution risk from follow-on offerings, competitive PI3Ka landscape (Novartis, Roche), and single-asset dependency. | High |
| AI confidence | High for descriptive facts and cash position, medium-low for forward scenarios due to binary clinical trial outcomes. | Medium confidence |
| Investment certainty | Low certainty. RLAY is suitable only for high-risk-tolerant investors who understand binary biotech risk and have a diversified portfolio. | Low |
RLAY AI stock forecast
The RLAY AI stock forecast uses scenario ranges around the $20.01 quote. Unlike profitable companies, biotech forecasts depend on pipeline value rather than earnings growth. All scenarios are highly uncertain and depend on Phase 3 zovegalisib data, regulatory outcomes, and competitive positioning.
$30 to $40
More likely if ReDiscover-2 Phase 3 data confirms zovegalisib superiority versus capivasertib in PIK3CA-mutant breast cancer, vascular anomaly data drives a second indication, and the company maintains its cash-efficient operating model without excessive dilution.
$18 to $28
More likely if Phase 3 data is positive but not transformative, requiring a combination strategy for full commercial potential, and the stock trades in line with analyst target range ($18-$28) and pipeline probability-adjusted NPV.
$5 to $12
More likely if Phase 3 misses primary endpoints, safety concerns emerge, competitive PI3Ka inhibitors (Roche inavolisib, Novartis alpelisib) maintain or expand market share, or significant equity dilution is required to fund operations.
RLAY AI technical analysis
RLAY AI technical analysis shows a strong uptrend as of the July 12, 2026 data cutoff. The stock trades above all key moving averages after a 436% yearly rally from a $3.03 52-week low. RSI near 66.3 signals momentum but approaches overbought territory. MACD remains positive at 1.47.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $20.01 | Quote near the upper end of the 52-week range after the year-long rally. |
| Near support | $19.27 to $17.68 | Financhill placed the 8-day SMA near $19.27 and 20-day SMA near $17.68, creating the first support zone. |
| Medium support | $15.11 to $14.60 | 50-day SMA near $15.11 and Bollinger Band (25) lower band near $14.60 form the medium support range. |
| Key long-term support | $10.33 to $11.24 | 200-day SMA near $10.33 and 200-day EMA near $11.24 mark the long-term trend reference. |
| Near resistance | $20.50 to $20.79 | The 52-week high near $20.79 and round-number resistance near $20.50 create the immediate overhead zone. |
| Momentum | RSI 66.3, MACD +1.47 | RSI at 66.3 indicates bullish momentum approaching the 70 overbought threshold. MACD positive and above signal line. |
| Volume | Average ~4.2 million shares | Below-average volume on the recent pullback suggests no urgent distribution, but a volume spike on a breakdown would be a warning. |
| Volatility | Beta 1.68, near 52-week high | High beta reflects the binary-risk biotech profile. The stock has moved from $3.03 to $20.79 in 12 months. |
| Invalidation | Close below $15 | A decisive close below the 50-day SMA area near $15 would signal the uptrend is under pressure. |
RLAY AI trading strategy
The RLAY AI trading strategy is a rules-based research framework for monitoring a binary-outcome biotech stock with strong momentum. It is not personal advice and should be paired with fresh trial data, filings, probability-weighted position sizing, and a defined invalidation level.
Watch for RLAY to hold above the $17.68 to $19.27 moving average zone on normal volume. A breakout above $20.79 (52-week high) on above-average volume could signal continued momentum toward analyst targets in the $24 to $28 range.
A close below $15 or a failed breakout after a Phase 3 data catalyst should invalidate the trend-following setup. Reduce position size before binary events.
If RLAY pulls back toward the $15 to $17 zone without negative clinical news, compare the drawdown with overall biotech sentiment and cash position before assuming the support is durable.
Biotech stocks can gap down 30-50% on negative data. Use strict stop-losses and limit position size to a risk budget you can lose entirely.
Track ReDiscover-2 Phase 3 enrollment completion, interim analysis dates, top-line data readouts, vascular anomaly data updates, RLY-8161 Phase 1/2 data, cash position and dilution risk from follow-on offerings, and competitive PI3Ka landscape developments.
Any significant delay in Phase 3 enrollment or data readout timeline is a negative signal. A secondary offering below $20 would dilute existing shareholders.
Investment research summary
Relay Therapeutics uses computational protein motion analysis (Dynamo platform) to discover small molecule drugs for targets that traditional methods cannot address. Customers are patients and physicians who need better precision medicines for genetically defined cancers and rare diseases.
The moat depends on clinical differentiation. Zovegalisib is designed to be mutant-selective PI3Ka inhibitor that avoids the hyperinsulinemia toxicity of orthosteric inhibitors like alpelisib. If Phase 3 data confirms superior tolerability with maintained efficacy, this selectivity creates a meaningful competitive advantage.
The thesis fails if ReDiscover-2 misses primary endpoints, if Roche inavolisib or another competitor captures the PI3Ka-mutant breast cancer market first, if vascular anomaly data disappoints, if cash requires dilutive financing before value inflection, or if the Dynamo platform fails to produce additional pipeline assets.
Management should be judged by clinical trial execution, capital allocation discipline (including the RLY-4008 outlicense to Elevar), cash runway management, and ability to advance the pipeline beyond the lead asset. Key-person risk exists around the core computational biology and clinical development team.
Precision oncology is a secular growth trend driven by decreasing sequencing costs, expanding biomarker identification, and regulatory willingness to accept targeted trial designs. PI3Ka is the most frequently mutated kinase in cancer, creating a large addressable market if tolerability can be improved.
At $20.01 and $4.36B market cap, RLAY prices in meaningful probability of Phase 3 success and commercial adoption. The margin of safety is limited given the binary risk. Analyst targets ($18-$28) suggest the stock is fairly valued to slightly undervalued assuming positive Phase 3 data.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| RLAY price | $20.01 | Google Finance quote snapshot | July 12, 2026 |
| Market capitalization | $4.36 billion, verified as $20.01 x 217.94 million shares | financial_rigor.py market cap verification | July 12, 2026 |
| Cash and equivalents | $642 million | Yahoo Finance balance sheet (mrq) | July 12, 2026 |
| TTM revenue | $10.68 million (collaboration revenue) | Yahoo Finance income statement | July 12, 2026 |
| TTM net income | -$272.7 million | Yahoo Finance income statement | July 12, 2026 |
| EPS (TTM) | -$1.56 | Yahoo Finance statistics | July 12, 2026 |
| Shares outstanding | 217.94 million | Google Finance / Yahoo Finance | July 12, 2026 |
| Book value per share | $2.95 | Calculated from cash, debt, and share count | July 12, 2026 |
| 52-week range | $3.03 to $20.79 | Google Finance 52-week range | July 12, 2026 |
| Analyst consensus | 11 Buy ratings, average target $25.08 | Yahoo Finance analyst targets | July 12, 2026 |
| Technical snapshot | 8-day SMA $19.27, 20-day SMA $17.68, 50-day SMA $15.11, RSI 66.3 | Financhill technical analysis snapshot | July 12, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell RLAY stock. Forecast scenarios are based on available public data, clinical trial disclosures, technical snapshots, and stated assumptions as of the data cutoff date and may be wrong. Clinical-stage biotech investments carry the risk of total capital loss. Always verify current filings, trial data, risks, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
